Stephen L. Lessnick, MD, PhD - Publications

2004-2015 Pediatrics, Oncological Sciences University of Utah, Salt Lake City, UT 
 2015- Department of Pediatrics and Center for Childhood Cancer and Blood Diseases The Ohio State University and Nationwide Children's Hospital 
Molecular Biology, Oncology, Human Development, Genetics, Pathology

70 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Theisen ER, Selich-Anderson J, Miller KR, Tanner JM, Taslim C, Pishas KI, Sharma S, Lessnick SL. Chromatin profiling reveals relocalization of lysine-specific demethylase 1 by an oncogenic fusion protein. Epigenetics. 1-20. PMID 32842875 DOI: 10.1080/15592294.2020.1805678  1
2020 Showpnil IA, Miller KR, Taslim C, Pishas KI, Lessnick SL, Theisen ER. Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis. Journal of Visualized Experiments : Jove. PMID 32658189 DOI: 10.3791/61564  1
2020 Luo W, Xu C, Phillips S, Gardenswartz A, Rosenblum JM, Ayello J, Lessnick SL, Hao HX, Cairo MS. Protein phosphatase 1 regulatory subunit 1A regulates cell cycle progression in Ewing sarcoma. Oncotarget. 11: 1691-1704. PMID 32477459 DOI: 10.18632/oncotarget.27571  1
2019 Abbott D, O'Brien S, Farnham JM, Young EL, Yap J, Jones K, Lessnick SL, Randall RL, Schiffman JD, Cannon-Albright LA. Increased risk for other cancers in individuals with Ewing sarcoma and their relatives. Cancer Medicine. PMID 31670911 DOI: 10.1002/cam4.2575  1
2019 Patel PO, Pishas KI, Taslim C, Selich-Anderson J, Theisen ER, Lessnick SL. Investigating the role of LSD2 as an epigenetic regulator in Ewing sarcoma. Oncotarget. 10: 3865-3878. PMID 31231465 DOI: 10.18632/oncotarget.26988  1
2019 Theisen ER, Miller KR, Showpnil IA, Taslim C, Pishas KI, Lessnick SL. Transcriptomic analysis functionally maps the intrinsically disordered domain of EWS/FLI and reveals novel transcriptional dependencies for oncogenesis. Genes & Cancer. 10: 21-38. PMID 30899417 DOI: 10.18632/genesandcancer.188  1
2019 Harlow ML, Chasse MH, Boguslawski EA, Sorensen KM, Gedminas JM, Kitchen-Goosen SM, Rothbart SB, Taslim C, Lessnick SL, Peck AS, Madaj ZB, Bowman MJ, Grohar PJ. Trabectedin Inhibits EWS-FLI1 and Evicts SWI/SNF from Chromatin in a Schedule Dependent Manner. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30723142 DOI: 10.1158/1078-0432.CCR-18-3511  1
2018 Pishas KI, Lessnick SL. Ewing sarcoma resistance to SP-2509 is not mediated through KDM1A/LSD1 mutation. Oncotarget. 9: 36413-36429. PMID 30559927 DOI: 10.18632/oncotarget.26326  1
2018 Pishas KI, Drenberg CD, Taslim C, Theisen ER, Johnson KM, Saund RS, Pop IL, Crompton BD, Lawlor ER, Tirode F, Mora J, Delattre O, Beckerle MC, Callen DF, Sharma S, ... Lessnick SL, et al. Therapeutic targeting of KDM1A/LSD1 in Ewing sarcoma with SP-2509 engages the endoplasmic reticulum stress response. Molecular Cancer Therapeutics. PMID 29997151 DOI: 10.1158/1535-7163.MCT-18-0373  1
2017 Johnson KM, Taslim C, Saund RS, Lessnick SL. Identification of two types of GGAA-microsatellites and their roles in EWS/FLI binding and gene regulation in Ewing sarcoma. Plos One. 12: e0186275. PMID 29091716 DOI: 10.1371/journal.pone.0186275  1
2017 Johnson KM, Mahler NR, Saund RS, Theisen ER, Taslim C, Callender NW, Crow JC, Miller KR, Lessnick SL. Role for the EWS domain of EWS/FLI in binding GGAA-microsatellites required for Ewing sarcoma anchorage independent growth. Proceedings of the National Academy of Sciences of the United States of America. PMID 28847958 DOI: 10.1073/pnas.1701872114  1
2017 Tanner JM, Bensard C, Wei P, Krah NM, Schell JC, Gardiner JD, Schiffman JD, Lessnick SL, Rutter J. EWS/FLI is a Master Regulator of Metabolic Reprogramming in Ewing Sarcoma. Molecular Cancer Research : McR. PMID 28720588 DOI: 10.1158/1541-7786.MCR-17-0182  1
2017 Gardiner JD, Abegglen LM, Huang X, Carter BE, Schackmann EA, Stucki M, Paxton CN, Randall RL, Amatruda JF, Putnam AR, Kovar H, Lessnick SL, Schiffman JD. C/EBPβ-1 promotes transformation and chemoresistance in Ewing sarcoma cells. Oncotarget. PMID 28148901 DOI: 10.18632/oncotarget.14847  1
2016 Pishas KI, Lessnick SL. Recent advances in targeted therapy for Ewing sarcoma. F1000research. 5. PMID 27635231 DOI: 10.12688/f1000research.8631.1  1
2016 Sankar S, Bell R, Stephens B, Zhuo R, Sharma S, Bearss DJ, Lessnick SL. Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma. Oncogene. PMID 27345405 DOI: 10.1038/onc.2016.142  1
2016 Cash T, McIlvaine E, Krailo MD, Lessnick SL, Lawlor ER, Laack N, Sorger J, Marina N, Grier HE, Granowetter L, Womer RB, DuBois SG. Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: A report from the Children's Oncology Group. Pediatric Blood & Cancer. PMID 27297500 DOI: 10.1002/pbc.26096  1
2016 Osgood CL, Maloney N, Kidd CG, Kitchen-Goosen SM, Segars LE, Gebregiorgis M, Woldemichael GM, He M, Sankar S, Lessnick SL, Kang MH, Smith MA, Turner L, Madaj ZB, Winn ME, et al. Identification of mithramycin analogs with improved targeting of the EWS-FLI1 transcription factor. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26979396 DOI: 10.1158/1078-0432.CCR-15-2624  1
2016 Vo KT, Edwards JV, Epling CL, Sinclair E, Hawkins DS, Grier HE, Janeway KA, Barnette P, McIlvaine E, Krailo M, Barkauskas DA, Matthay KK, Womer RB, Gorlick R, Lessnick SL, et al. Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26861456 DOI: 10.1158/1078-0432.CCR-15-2516  1
2016 Theisen ER, Pishas KI, Saund RS, Lessnick SL. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting. Oncotarget. PMID 26848860 DOI: 10.18632/oncotarget.7124  1
2015 Fadul J, Bell R, Hoffman LM, Beckerle MC, Engel ME, Lessnick SL. EWS/FLI utilizes NKX2-2 to repress mesenchymal features of Ewing sarcoma. Genes & Cancer. 6: 129-43. PMID 26000096  1
2015 Lerman DM, Monument MJ, McIlvaine E, Liu XQ, Huang D, Monovich L, Beeler N, Gorlick RG, Marina NM, Womer RB, Bridge JA, Krailo MD, Randall RL, Lessnick SL. Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the Children's Oncology Group. Pediatric Blood & Cancer. 62: 759-65. PMID 25464386 DOI: 10.1002/pbc.25340  1
2014 Zhuo R, Kosak KM, Sankar S, Wiles ET, Sun Y, Zhang J, Ayello J, Prestwich GD, Shami PJ, Cairo MS, Lessnick SL, Luo W. Targeting Glutathione S-transferase M4 in Ewing sarcoma. Frontiers in Pediatrics. 2: 83. PMID 25147782 DOI: 10.3389/fped.2014.00083  1
2014 Monument MJ, Johnson KM, McIlvaine E, Abegglen L, Watkins WS, Jorde LB, Womer RB, Beeler N, Monovich L, Lawlor ER, Bridge JA, Schiffman JD, Krailo MD, Randall RL, Lessnick SL. Clinical and biochemical function of polymorphic NR0B1 GGAA-microsatellites in Ewing sarcoma: a report from the Children's Oncology Group. Plos One. 9: e104378. PMID 25093581 DOI: 10.1371/journal.pone.0104378  1
2014 Chaturvedi A, Hoffman LM, Jensen CC, Lin YC, Grossmann AH, Randall RL, Lessnick SL, Welm AL, Beckerle MC. Molecular dissection of the mechanism by which EWS/FLI expression compromises actin cytoskeletal integrity and cell adhesion in Ewing sarcoma. Molecular Biology of the Cell. 25: 2695-709. PMID 25057021 DOI: 10.1091/mbc.E14-01-0007  1
2014 Sankar S, Theisen ER, Bearss J, Mulvihill T, Hoffman LM, Sorna V, Beckerle MC, Sharma S, Lessnick SL. Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4584-97. PMID 24963049 DOI: 10.1158/1078-0432.CCR-14-0072  1
2014 Kumar P P, Emechebe U, Smith R, Franklin S, Moore B, Yandell M, Lessnick SL, Moon AM. Coordinated control of senescence by lncRNA and a novel T-box3 co-repressor complex. Elife. 3. PMID 24876127 DOI: 10.7554/eLife.02805  0.4
2013 Wiles ET, Bell R, Thomas D, Beckerle M, Lessnick SL. ZEB2 Represses the Epithelial Phenotype and Facilitates Metastasis in Ewing Sarcoma. Genes & Cancer. 4: 486-500. PMID 24386509 DOI: 10.1177/1947601913506115  1
2013 Sankar S, Gomez NC, Bell R, Patel M, Davis IJ, Lessnick SL, Luo W. EWS and RE1-Silencing Transcription Factor Inhibit Neuronal Phenotype Development and Oncogenic Transformation in Ewing Sarcoma. Genes & Cancer. 4: 213-23. PMID 24069508 DOI: 10.1177/1947601913489569  1
2013 Sankar S, Tanner JM, Bell R, Chaturvedi A, Randall RL, Beckerle MC, Lessnick SL. A novel role for keratin 17 in coordinating oncogenic transformation and cellular adhesion in Ewing sarcoma. Molecular and Cellular Biology. 33: 4448-60. PMID 24043308 DOI: 10.1128/MCB.00241-13  1
2013 Shukla N, Schiffman J, Reed D, Davis IJ, Womer RB, Lessnick SL, Lawlor ER. Biomarkers in Ewing Sarcoma: The Promise and Challenge of Personalized Medicine. A Report from the Children's Oncology Group. Frontiers in Oncology. 3: 141. PMID 23761859 DOI: 10.3389/fonc.2013.00141  1
2013 Wiles ET, Lui-Sargent B, Bell R, Lessnick SL. BCL11B is up-regulated by EWS/FLI and contributes to the transformed phenotype in Ewing sarcoma. Plos One. 8: e59369. PMID 23527175 DOI: 10.1371/journal.pone.0059369  1
2013 Borinstein SC, Beeler N, Block JJ, Gorlick R, Grohar P, Jedlicka P, Krailo M, Morris C, Phillips S, Siegal GP, Lawlor ER, Lessnick SL. A Decade in Banking Ewing Sarcoma: A Report from the Children's Oncology Group. Frontiers in Oncology. 3: 57. PMID 23519678 DOI: 10.3389/fonc.2013.00057  1
2013 Sankar S, Bell R, Stephens B, Zhuo R, Sharma S, Bearss DJ, Lessnick SL. Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma. Oncogene. 32: 5089-100. PMID 23178492 DOI: 10.1038/onc.2012.525  1
2012 Monument MJ, Johnson KM, Grossmann AH, Schiffman JD, Randall RL, Lessnick SL. Microsatellites with macro-influence in ewing sarcoma. Genes. 3: 444-60. PMID 24704979 DOI: 10.3390/genes3030444  1
2012 Monument MJ, Lessnick SL, Schiffman JD, Randall RT. Microsatellite instability in sarcoma: fact or fiction? Isrn Oncology. 2012: 473146. PMID 23401795 DOI: 10.5402/2012/473146  1
2012 Chaturvedi A, Hoffman LM, Welm AL, Lessnick SL, Beckerle MC. The EWS/FLI Oncogene Drives Changes in Cellular Morphology, Adhesion, and Migration in Ewing Sarcoma. Genes & Cancer. 3: 102-16. PMID 23050043 DOI: 10.1177/1947601912457024  1
2012 Jahromi MS, Putnam AR, Druzgal C, Wright J, Spraker-Perlman H, Kinsey M, Zhou H, Boucher KM, Randall RL, Jones KB, Lucas D, Rosenberg A, Thomas D, Lessnick SL, Schiffman JD. Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma. Cancer Genetics. 205: 391-404. PMID 22868000 DOI: 10.1016/j.cancergen.2012.05.012  1
2012 Beck R, Monument MJ, Watkins WS, Smith R, Boucher KM, Schiffman JD, Jorde LB, Randall RL, Lessnick SL. EWS/FLI-responsive GGAA microsatellites exhibit polymorphic differences between European and African populations. Cancer Genetics. 205: 304-12. PMID 22749036 DOI: 10.1016/j.cancergen.2012.04.004  1
2012 Kovar H, Alonso J, Aman P, Aryee DN, Ban J, Burchill SA, Burdach S, De Alava E, Delattre O, Dirksen U, Fourtouna A, Fulda S, Helman LJ, Herrero-Martin D, Hogendoorn PC, ... ... Lessnick SL, et al. The first European interdisciplinary ewing sarcoma research summit. Frontiers in Oncology. 2: 54. PMID 22662320 DOI: 10.3389/fonc.2012.00054  1
2012 Spraker HL, Price SL, Chaturvedi A, Schiffman JD, Jones KB, Lessnick SL, Beckerle M, Randall RL. The clone wars - revenge of the metastatic rogue state: the sarcoma paradigm. Frontiers in Oncology. 2: 2. PMID 22649772 DOI: 10.3389/fonc.2012.00002  1
2012 Luo W, Milash B, Dalley B, Smith R, Zhou H, Dutrow N, Cairns BR, Lessnick SL. Antibody detection of translocations in Ewing sarcoma. Embo Molecular Medicine. 4: 453-61. PMID 22419563 DOI: 10.1002/emmm.201200225  1
2011 Luo W, Kinsey M, Schiffman JD, Lessnick SL. Glutathione s-transferases in pediatric cancer. Frontiers in Oncology. 1: 39. PMID 22655244 DOI: 10.3389/fonc.2011.00039  1
2011 Joyner DE, Jones KB, Lessnick SL, Schiffman JD, Randall RL. Potential for modulation of the fas apoptotic pathway by epidermal growth factor in sarcomas. Sarcoma. 2011: 847409. PMID 22135505 DOI: 10.1155/2011/847409  1
2011 Sankar S, Lessnick SL. Promiscuous partnerships in Ewing's sarcoma. Cancer Genetics. 204: 351-65. PMID 21872822 DOI: 10.1016/j.cancergen.2011.07.008  1
2011 Jones KB, Haldar M, Schiffman JD, Cannon-Albright L, Lessnick SL, Sharma S, Capecchi MR, Randall RL. Of mice and men: opportunities to use genetically engineered mouse models of synovial sarcoma for preclinical cancer therapeutic evaluation. Cancer Control : Journal of the Moffitt Cancer Center. 18: 196-203. PMID 21666582  1
2011 Jones KB, Schiffman JD, Kohlmann W, Randall RL, Lessnick SL, Cannon-Albright LA. Complex genotype sarcomas display familial inheritance independent of known cancer predisposition syndromes Cancer Epidemiology Biomarkers and Prevention. 20: 751-757. PMID 21242332 DOI: 10.1158/1055-9965.EPI-10-1174  1
2011 Kowalewski AA, Randall RL, Lessnick SL. Cell Cycle Deregulation in Ewing's Sarcoma Pathogenesis. Sarcoma. 2011: 598704. PMID 21052502 DOI: 10.1155/2011/598704  0.6
2010 Gangwal K, Close D, Enriquez CA, Hill CP, Lessnick SL. Emergent Properties of EWS/FLI Regulation via GGAA Microsatellites in Ewing's Sarcoma. Genes & Cancer. 1: 177-187. PMID 20827386 DOI: 10.1177/1947601910361495  0.36
2010 Toomey EC, Schiffman JD, Lessnick SL. Recent advances in the molecular pathogenesis of Ewing's sarcoma. Oncogene. 29: 4504-16. PMID 20543858 DOI: 10.1038/onc.2010.205  1
2010 van Doorninck JA, Ji L, Schaub B, Shimada H, Wing MR, Krailo MD, Lessnick SL, Marina N, Triche TJ, Sposto R, Womer RB, Lawlor ER. Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 1989-94. PMID 20308669 DOI: 10.1200/JCO.2009.24.5845  1
2009 Kinsey M, Smith R, Iyer AK, McCabe ER, Lessnick SL. EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma. Cancer Research. 69: 9047-55. PMID 19920188 DOI: 10.1158/0008-5472.CAN-09-1540  1
2009 Luo W, Gangwal K, Sankar S, Boucher KM, Thomas D, Lessnick SL. GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance. Oncogene. 28: 4126-32. PMID 19718047 DOI: 10.1038/onc.2009.262  1
2009 Lessnick SL, Dei Tos AP, Sorensen PH, Dileo P, Baker LH, Ferrari S, Hall KS. Small round cell sarcomas. Seminars in Oncology. 36: 338-46. PMID 19664494 DOI: 10.1053/j.seminoncol.2009.06.006  1
2009 DuBois SG, Krailo MD, Lessnick SL, Smith R, Chen Z, Marina N, Grier HE, Stegmaier K. Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group. Pediatric Blood & Cancer. 52: 324-7. PMID 18989890 DOI: 10.1002/pbc.21822  0.4
2008 Gangwal K, Lessnick SL. Microsatellites are EWS/FLI response elements: genomic "junk" is EWS/FLI's treasure. Cell Cycle (Georgetown, Tex.). 7: 3127-32. PMID 18927503 DOI: 10.4161/cc.7.20.6892  0.36
2008 Gangwal K, Sankar S, Hollenhorst PC, Kinsey M, Haroldsen SC, Shah AA, Boucher KM, Watkins WS, Jorde LB, Graves BJ, Lessnick SL. Microsatellites as EWS/FLI response elements in Ewing's sarcoma. Proceedings of the National Academy of Sciences of the United States of America. 105: 10149-54. PMID 18626011 DOI: 10.1073/pnas.0801073105  1
2008 Meyer JS, Nadel HR, Marina N, Womer RB, Brown KL, Eary JF, Gorlick R, Grier HE, Randall RL, Lawlor ER, Lessnick SL, Schomberg PJ, Kailo MD. Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group Bone Tumor Committee. Pediatric Blood & Cancer. 51: 163-70. PMID 18454470 DOI: 10.1002/pbc.21596  1
2008 Owen LA, Kowalewski AA, Lessnick SL. EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma Plos One. 3. PMID 18414662 DOI: 10.1371/journal.pone.0001965  1
2007 Potikyan G, Savene RO, Gaulden JM, France KA, Zhou Z, Kleinerman ES, Lessnick SL, Denny CT. EWS/FLI1 regulates tumor angiogenesis in Ewing's sarcoma via suppression of thrombospondins. Cancer Research. 67: 6675-84. PMID 17638877 DOI: 10.1158/0008-5472.CAN-06-4140  0.56
2007 Yagoda N, von Rechenberg M, Zaganjor E, Bauer AJ, Yang WS, Fridman DJ, Wolpaw AJ, Smukste I, Peltier JM, Boniface JJ, Smith R, Lessnick SL, Sahasrabudhe S, Stockwell BR. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature. 447: 864-8. PMID 17568748 DOI: 10.1038/nature05859  1
2007 Stegmaier K, Wong JS, Ross KN, Chow KT, Peck D, Wright RD, Lessnick SL, Kung AL, Golub TR. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. Plos Medicine. 4: e122. PMID 17425403 DOI: 10.1371/journal.pmed.0040122  1
2007 Haldar M, Hancock JD, Coffin CM, Lessnick SL, Capecchi MR. A conditional mouse model of synovial sarcoma: insights into a myogenic origin. Cancer Cell. 11: 375-88. PMID 17418413 DOI: 10.1016/j.ccr.2007.01.016  1
2006 Braunreiter CL, Hancock JD, Coffin CM, Boucher KM, Lessnick SL. Expression of EWS-ETS fusions in NIH3T3 cells reveals significant differences to Ewing's sarcoma. Cell Cycle (Georgetown, Tex.). 5: 2753-9. PMID 17172842  1
2006 Kinsey M, Smith R, Lessnick SL. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma. Molecular Cancer Research : McR. 4: 851-9. PMID 17114343 DOI: 10.1158/1541-7786.MCR-06-0090  0.4
2006 Owen LA, Lessnick SL. Identification of target genes in their native cellular context: An analysis of EWS/FLI in Ewing's sarcoma Cell Cycle. 5: 2049-2053. PMID 16969112  1
2006 Davis IJ, Kim JJ, Ozsolak F, Widlund HR, Rozenblatt-Rosen O, Granter SR, Du J, Fletcher JA, Denny CT, Lessnick SL, Linehan WM, Kung AL, Fisher DE. Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers. Cancer Cell. 9: 473-84. PMID 16766266 DOI: 10.1016/j.ccr.2006.04.021  0.56
2006 Smith R, Owen LA, Trem DJ, Wong JS, Whangbo JS, Golub TR, Lessnick SL. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Cancer Cell. 9: 405-16. PMID 16697960 DOI: 10.1016/j.ccr.2006.04.004  1
2003 Gozani O, Karuman P, Jones DR, Ivanov D, Cha J, Lugovskoy AA, Baird CL, Zhu H, Field SJ, Lessnick SL, Villasenor J, Mehrotra B, Chen J, Rao VR, Brugge JS, et al. The PHD finger of the chromatin-associated protein ING2 functions as a nuclear phosphoinositide receptor. Cell. 114: 99-111. PMID 12859901 DOI: 10.1016/S0092-8674(03)00480-X  1
2003 Dolma S, Lessnick SL, Hahn WC, Stockwell BR. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell. 3: 285-96. PMID 12676586 DOI: 10.1016/S1535-6108(03)00050-3  1
2002 Lessnick SL, Dacwag CS, Golub TR. The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. Cancer Cell. 1: 393-401. PMID 12086853  0.4
Show low-probability matches.